

BLISS GVS PHARMA LIMITED Registered Office: 102, Hyde Park, Saklvihar Road, Andheri (East), Mumbai - 400 072.

	UNAUDITED FINANCIAL RESULTS FOR THE QUA		TPED 50.	JO.2013	100	
_					(Rs. 1	
1		-		NDALONE		
-	PARTICULARS	QUARTER ENDED			YEAR	
+		39.06.2013 (UNAUDITED		30.06,2012 (UNAUDITED	31.03	
1	Income From Operations		7 (1001120)	TOWNODITED	(AUD	
Ţ	(a) Net Sales (Net of Excise Duty)		1	ĺ	1	
	(b) Other Operating Income	7,371.75		6,374,16	34,8	
	Total Income From Operations(Net)	185.92	250.70	59.66	5	
1	Expenses	7,557.67	10,263.41	6,433.82	35,3	
Ĺ	(a) Consumption of Raw Materials	1]		,-	
l	(b) Purchase of Traded Goods	3,436.28	5,606.69	3,517,49	18,84	
l	(c) (Increase)/Decrease in Stock in Trade	159.46	52.50	60.17	36	
ļ	(d) Employee Benefit Expenses	506.64	(94.65)	(209.42)	(5	
ĺ	(e) Dapreciation / Amortisation	292.91	272.90	196.62	98	
l	(f) Other Expenditure	104.97	119.71	106.74	44	
	Total Expenses	1,841,28	2,677.22	682,79	5,60	
	Profit from Operations before other Income & Finance Cost & Exceptional Items (1-2)	6,341.54	8,634.39	4,354.39	25,73	
	Other Income	1,216.13	1,629.02	2,079.43	9,63	
	Profit From Ordinary Activities Before Finance Cost (3+4)	1,617.56	731.82	394.64	1,50	
	Finance Cost	2,833.69	2,360.84	2,474.07	11,13	
	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	188.71	221,13	80.57	65	
	Exceptional items (5-6)	2,644.93	2,139.71	2,393.50	10,48	
	For the Property of the Board of Articles and the Company of the C	J i	-	- 1		
CMM	Tax Expense (Including Deferred Tax)	2,644.98	2 139.71	2,393.50	10.48	
	Mat Profit From Ordinary Activities Affar Fax (9.1 (8)	819.94	1,569.28	704.01	4.81	
Wr.ing	Extra Ordinary Items (Net of Tax Expenses)	1,825.04	570.4Z	7,689,497	5 66	
1002	Mar Profit Ch. 182 Day 2017 (4 St.	- !	- 1	- }		
ATGOX I	Nat Profit For The Period (111 - 72) Paid - Up Equity Capital	1,825,04	570.42	1,689,49	5.66	
i	Reserves Excluding Revaluation Reserve (As per Balance Sheet)	1,031.47	1,031.47	1,031.47	1,03	
wii	Basic and Unioned EPS (Not Annualisad)			·	24,842	
		1.77	0.55	1.64	9	
۱ -						
J	Particulars of Shareholding					
,	Aggregate of Non-Promoter Shareholding	[1		
•	No. of Shares (Face Value Rs.1/- Each)	38156842	36187842	36187842	201000	
	Percentage of Shareholding (%)	35.05	35.08	35.08	361868	
٤	Promoter and Promoter Group Shareholding	00.00	33.00	35.08	35	
F	A) Pledge/ Encumbered			ì		
-	No. of Shares (Face Value Re.1/- Each)		[_	
-	Percentage of Shares (As % of the total share	_	- 1	- 1		
	Holding of Promoter & Promoter Group)		.	•	-	
-	Percentage of Shares (As % of the total share	_		.		
	Capital of the Company)	-	•	*	-	
В	Non - Encumbered					
-	No. of Shares (Face Value Re. 1/- Each)	66989830	66958830	66958830	000000	
-	Percentage of Shares (As % of the total share	00000000	00000000	0000000	669598	
	Holding of Promoter & Promoter Group)	100.00	100.00	100.00	400	
-	Percentage of Shares (As % of the total Share Capital of the Company)	64.95	64.92	100.00 64.92	180,	
_		04.00	04.52	04.92	64.	
	PARTICULARS	Q	uarter Ended 3	0 June 2013		
Ħ	Westor Complaints		****			
P	ending at the beginning of the quarter	-				
R	eceived during the quarter		1			
	isposed off during the quarter		•			
	EMAINING UNSOLVED AT THE END OF THE QUARTER		1 -			
	TANK TO THE PARTY OF THE PARTY			m^		
Th	e company operates primarily in the pharmaceutical business and honce has only one separable and	ment				
Th	e company operates primarily in the pharmaceutical business and hence has only one reportable seg uring the quarter the company has formed a subsidiary with 51% stake in the name of Lifcon Labs Pr	ment.				

- The above results were reviewed by the Audit Committee & were there after approved by The Board at its meeting held on August 14th 2013.
- The figures for the Quarter Ended March 31, 2013 are the balancing figures between the Audited figures in respect of the full financial year ended March 31, 2013 and the published year to date figures up to the third Quarter Ended December 31, 2012
- Figures for the Previous Year/Quarters have been Regrouped/Rearranged wherever necessary.

Place : Mumbal Date : 14-08-2013

FOR BLISS GVS PHARMA LIMITED SD/-S. N. KAMATH MANAGING DIRECTOR